<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02260505</url>
  </required_header>
  <id_info>
    <org_study_id>IMADGIST</org_study_id>
    <secondary_id>2013-001372-37</secondary_id>
    <nct_id>NCT02260505</nct_id>
  </id_info>
  <brief_title>Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)</brief_title>
  <acronym>ImadGist</acronym>
  <official_title>A Randomized Multicenter Phase III Trial Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2 arms study concerning patients with primary GIST who followed an Imatinib
      adjuvant treatment for 3 years after surgery and who have a high risk of recurrence.

      In the first arm, patients will continue Imatinib treatment for 3 more years, allowing to
      determine if the continuation of this treatment is efficient for disease control, in terms of
      Disease Free Survival improvement.

      In the second arm, patients will discontinue the Imatinib treatment, as standard practice.
      This arm will allow to determine if the re-introduction of Imatinib at relapse is still an
      efficient treatment for the control of disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastrointestinal stromal tumours (GISTs) are rare mesenchymal neoplasms, mostly diagnosed
      between 55 and 60 years of age, which account for 5% of all sarcomas. Worldwide annual
      incidence is approximately 12 cases per million people, corresponding to approximately 800
      new cases per year in France.

      A large majority of GISTs harbour activating mutations in the proto-oncogenes KIT and/or
      PDGFRA, both coding cell-surface cytokine receptors with tyrosine-protein kinase activity.

      Imatinib mesilate (GlivecÂ®, Novartis Pharma SAS) is a selective tyrosine kinase inhibitor,
      leading to inhibition of KIT and PDGFRA signalling pathways. The introduction of imatinib has
      revolutionised the therapeutic management of GIST patients and has provided an unprecedented
      demonstration of the clinical benefit of a targeted therapy for patients with
      advanced/metastatic solid tumors. First results from prospective trials conducted with
      imatinib in GIST patients have demonstrated a 300% increase in median overall survival, and a
      likely 100% increase in 5 and 10-year survival as compared to cytotoxic chemotherapy.

      The successful use of imatinib in the treatment of advanced GISTs and the significant risk of
      recurrence of advanced GISTs have prompted the investigation of the clinical benefit of
      imatinib as a post-operative adjuvant therapy. Two prospective randomized Phase III trials
      have demonstrated that adjuvant imatinib treatment significantly prolong overall survival
      (OS) and recurrence-free survival (RFS) when given for 3 years. To date, imatinib is also
      indicated in the adjuvant setting after complete resection of primary, localized,
      KIT-positive GIST at high risk of recurrence. However, the optimal treatment duration remains
      unclear and it should be determined whether

        1. prolonged use of adjuvant imatinib beyond 3 years may enable to reduce the risk of GIST
           recurrence and to improve overall survival, and

        2. imatinib rechallenge is efficient for treating recurrence after completion of 3-year
           adjuvant imatinib therapy.

      This trial is an open-label, randomized, multicenter phase III study aiming to determine the
      clinical impact of maintaining imatinib treatment beyond 3 years in the adjuvant setting for
      patients with resected GISTs at high risk of recurrence according to the National
      Comprehensive Cancer Network Task Force on GIST (NCCN) risk classification.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 24, 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>6 years (i.e. at the the time of last patient last visit)</time_frame>
    <description>Time from the date of randomisation to the first documented relapse or death due to any cause. Patients with no event at the time of analysis will be censored at the date of the last adequate tumour assessment. The results will be analyzed according to the study arm and randomization strata to wich patients were assigned.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>6 years (i.e. at the the time of last patient last visit)</time_frame>
    <description>Time from the date of randomization until the date of death due to any cause and censored at the date of last contact for patients alive at last contact. The results will be analyzed according to the study arm and randomization strata to wich patients were assigned.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Secondary Resistance (TSR)</measure>
    <time_frame>6 years (i.e. at the the time of last patient last visit)</time_frame>
    <description>Time from the date of randomization until the date of first relapse under Imatinib treatment (i.e first relapse in the &quot;Imatinib maintenance arm&quot; and relapse after reintroduction of Imatinib in the &quot;Interruption of Imatinib arm&quot;). The results will be analyzed according to the study arm and randomization strata to wich patients were assigned.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients in Complete Response (%CR) in interruption arm after reintroduction of Imatinib</measure>
    <time_frame>6 years (i.e. at the the time of last patient last visit)</time_frame>
    <description>Percentage of patients in Complete Response (CR) after reintroduction of Imatinib treatment for patients assigned to the interruption arm and who experience GIST recurrence. CR is assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Adverse Events (AE)</measure>
    <time_frame>6 years (i.e. at the the time of last patient last visit)</time_frame>
    <description>The assessment of safety will be based mainly on the frequency of AE based on the Common Toxicity Criteria version 4 grade. AE will be coded according to the Medical Dictionary for Regulatory Activities (MedDRA). Descriptive statistics will be provided for characterizing and assessing patient tolerance to treatment. Patients with at least either one serious AE, or one grade 3-4, or one AE requiring the interruption of study treatment, will be described by study arm and compared using a Pearson's Chi2 test or a Fisher's exact test, if adequate. Patients will be analyzed according the duration of exposure to imatinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Quality of Life (QoL)</measure>
    <time_frame>6 years (i.e at the the time of last patient last visit)</time_frame>
    <description>QoL will be assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire (QLQ-C30). Descriptive statistics (e.g. means and medians) will be used to summarize the scored scales at it scheduled assessment time point of the questionnaire. The distribution of time to definitive health-related QoL deterioration by study arms will be estimated using the Kaplan-Meier method. The time to definitive deterioration is defined as the time from the date of randomization to the date of event, wich is defined as &gt; 10 points decrease from baseline of QLQ-C30 global score (items 29 and 30) or death due to any cause. If patient has not had an event, time to QoL deterioration will be censored at the date of last adequate evaluation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>Gastrointestinal Stromal Tumors</condition>
  <condition>Resected Gastrointestinal Stromal Tumors</condition>
  <condition>Non-metastatic</condition>
  <condition>High Risk of Recurrence</condition>
  <condition>KIT Gene Mutation</condition>
  <arm_group>
    <arm_group_label>Imatinib maintenance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maintenance of Imatinib at the last dose routinely taken by the patient in the 3 years period prior to randomization (either 300 or 400 mg/day). Increase dose up to 800 mg/day if relapse according to RECIST 1.1 criteria. Any relapse/progressive disease at 800 mg/day will lead to Imatinib permanent discontinuation and study discontinuation. In case of toxicity, Imatinib dose will be interrupted or adjusted in accordance with Imatinib Specific Product Characteristics (SPC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imatinib Interruption</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Treatment corresponding to standard practice : interruption of Imatinib from the day of randomization. Reintroduction of Imatinib at 400 mg/day after first relapse according to RECIST 1.1 criteria; Then increase dose to 800 mg/day after 2d relapse. Any relapse/progressive disease at 800 mg/day will lead to Imatinib permanent discontinuation and study discontinuation. In case of toxicity, Imatinib dose will be interrupted or adjusted in accordance with Imatinib SPC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib maintenance</intervention_name>
    <description>Either 300 or 400 mg/day in accordance with the last dose routinely taken by the patient in the 3-year period before randomization. The treatment will be orally taken at time of meal with a large glass of water</description>
    <arm_group_label>Imatinib maintenance</arm_group_label>
    <other_name>Glivec</other_name>
    <other_name>Imatinib mÃ©silate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â¥ 18 years at the day of consenting to the study

          -  Patients must have histologically confirmed diagnosis of localized GIST with
             documented KIT (CD117) positivity (by polyclonal DAKO antibody staining)

          -  Documented macroscopically complete surgical R0 or R1 resection of primary GIST lesion
             with no evidence of residual lesions or metastases on the baseline CT-scan or MRI
             performed no more than 4 weeks before randomization.

          -  Risk of tumor recurrence â¥ 35% according to National Comprehensive Cancer Network Task
             Force on GIST (NCCN) risk classification (Demetri et al., 2010) (See Appendix 1)

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2

          -  Patients must be under imatinib treatment (at 300 or 400 mg/day) initiated immediately
             after resection and maintained for 3 years (i.e. 36 months Â± 3 months at the time of
             randomization) with no more than 3 consecutive months or 6 months in total of
             interruption during these past 3 years.

          -  Patients must have normal organ and bone marrow function at baseline as defined below:

               -  absolute neutrophil count (ANC) â¥ 1.5 G/L, platelet count â¥ 100 G/L, and
                  haemoglobin of â¥ 9 g/dL).

               -  Serum total bilirubin â¤ 1.5 (upper limit of normal (ULN), aspartate
                  aminotransferase (AST) and alanine aminotransferase (ALT) â¤ 3 x ULN (or 5 x ULN
                  in case of hepatic metastases at time of reintroduction)

               -  Adequate renal function assessed by at least one of the following:

                    -  1) Serum creatinine â¤ 1.5 x ULN or

                    -  2) creatinine clearance estimate â¥ 50 mL/min (as calculated according to
                       Cockcroft-Gault formula or MDRD formula for patients &gt; 65 years).

          -  Recovered from prior anti-neoplasia treatment-related toxicity (persistent
             treatment-related toxicity &lt; Grade 2 as per Common Toxicity Criteria for Adverse
             Effects (CTCAE) v4 are accepted)

          -  Women of childbearing potential are required to have a negative serum pregnancy test
             within 72 hours prior to randomization. A positive urine test must be confirmed by a
             serum pregnancy test

          -  Patient must use effective contraception at least 4 weeks prior to study entry, during
             the study participation and for at least 30 days post-treatment (not applicable for
             women of non-childbearing potential)

          -  Ability to understand and willingness for follow-up visits.

          -  Covered by a medical insurance.

          -  Signed and dated informed consent document indicating that the patient has been
             informed of all aspects of the trial prior to enrolment.

        Exclusion Criteria:

          -  Pregnant or breastfeeding women

          -  Patient concurrently using other approved or investigational antineoplastic agents

          -  Any contra-indication to imatinib treatment as per GlivecÂ® SPC

          -  Patient with GIST harboring the mutation D842V in PDGFRA

          -  Major concurrent disease affecting cardiovascular system, liver, kidneys,
             haematopoietic system or else considered as clinically important by the investigator
             and that could be incompatible with patient's participation in this trial or would
             likely interfere with study procedures or results.

          -  Prior history of other malignancies other than study disease (except for basal cell or
             squamous cell carcinoma of the skin or carcinoma in situ of the cervix) unless the
             patient has been free of the disease for at least 3 years.

          -  Patient receiving concurrent treatment with warfarin (acceptable alternative:
             low-molecular weight heparin) or any prohibited concomitant and/or concurrent
             medications

          -  Patient with Grade III/IV cardiac problems as defined by the New York Heart
             Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6
             months of study)

          -  Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.

          -  Major surgery within 2 weeks prior to study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Yves Blay, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre LÃ©on BÃ©rard, Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Yves Blay, Pr</last_name>
    <phone>+33 4 78 78 27 57</phone>
    <email>jean-yves.blay@lyon.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <state>Bouches du RhÃ´ne</state>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>FranÃ§ois BERTUCCI, Pr</last_name>
      <phone>+33 4 91 22 35 37</phone>
      <email>bertuccif@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>FranÃ§ois BERTUCCI, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Slimane DERMERCHE, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Delphine PERROT, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Magali PROVANSAL, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire La Timone</name>
      <address>
        <city>Marseille</city>
        <state>Bouches du RhÃ´ne</state>
        <zip>13386</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence DUFFAUD, Pr</last_name>
      <phone>+33 4 91 38 57 08</phone>
      <email>florence.duffaud@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Florence DUFFAUD, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>SÃ©bastien SALAS, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de BesanÃ§on - HÃ´pital Minjoz</name>
      <address>
        <city>BesanÃ§on</city>
        <state>Doubs</state>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elsa KALBACHER, Doctor</last_name>
      <phone>+ 33 3 81 66 81 66</phone>
      <email>ekalbacher@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>LoÃ¯c CHAIGNEAU, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elsa KALBACHER, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut BergoniÃ©</name>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine ITALIANO, Dr</last_name>
      <phone>+33 5 24 07 19 47</phone>
      <email>a.italiano@bordeaux.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Antoine ITALIANO, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie COUSIN, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maud TOULMONDE, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Toulouse Purpan</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosine GUIMBAUD, Pr</last_name>
      <phone>+33 5 61 77 96 49</phone>
      <email>Guimbaud.r@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Rosine GUIMBAUD, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre RÃ©gional de Lutte contre le Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <state>HÃ©rault</state>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Didier CUPISSOL, Dr</last_name>
      <phone>+33 4 67 61 31 83</phone>
      <email>didier.cupissol@icm.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Didier CUPISSOL, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nelly FIRMIN, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP HÃ´pital EuropÃ©en Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno LANDI, Dr</last_name>
      <phone>+33 1 56 09 35 55</phone>
      <email>bruno.landi@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno LANDI, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Laure POINTET, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de CancÃ©rologie de l'Ouest</name>
      <address>
        <city>Saint-Herblain</city>
        <state>Loire Atlantique</state>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth BOMPAS, Dr</last_name>
      <phone>+33 2 40 67 99 39</phone>
      <email>emmanuelle.bompas@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Elisabeth BOMPAS, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>FrÃ©dÃ©ric ROLLAND, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Damien VANSTEENE, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie ROBERT, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Akila BENINE DANDEC, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathilde COLOMBIE, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carole GOURMELON, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Audrey ROLLOT, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de cancÃ©rologie LUCIEN NEUWIRTH</name>
      <address>
        <city>Saint-priest-en-jarez</city>
        <state>Loire</state>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier COLLARD, Dr</last_name>
      <phone>00 334 77 91 70 34</phone>
      <email>olivier.collard@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier COLLARD, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cecile VASSAL, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier universitaire Robert DebrÃ©</name>
      <address>
        <city>Reims</city>
        <state>Marne</state>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier BOUCHE, Pr</last_name>
      <phone>+33 3 26 78 71 72</phone>
      <email>obouche@chu-reims.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier BOUCHE, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien VOLET, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de CancÃ©rologie de Lorraine</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <state>Meurthe et Moselle</state>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria RIOS, Dr</last_name>
      <phone>+33 3 83 59 85 66</phone>
      <email>m.rios@nancy.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Maria RIOS, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas PENEL, Pr</last_name>
      <phone>+33 3 20 29 59 20</phone>
      <email>n-penel@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Farid EL HAJBI, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas PENEL, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charlotte PEUGNIEZ, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre LÃ©on BÃ©rard</name>
      <address>
        <city>Lyon</city>
        <state>RhÃ´ne</state>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Yves BLAY, Pr</last_name>
      <phone>+33 4 78 78 27 57</phone>
      <email>jean-yves.blay@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Yves BLAY, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivia BALLY, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe CASSIER, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle RAY-COQUART, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie MARQUES, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthieu SARABI, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de CancÃ©rologie Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val de Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axel LE CESNE, Dr</last_name>
      <phone>+33 1 42 11 43 16</phone>
      <email>axel.lecesne@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Axel LE CESNE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien DOMONT, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah DUMONT, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier MIR, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP HÃ´pital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle TROUILLOUD, Dr</last_name>
      <phone>+33 1 48 29 23 29</phone>
      <email>isabelle.trouilloud@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Pauline AFCHAIN, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry ANDRE, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Line GARCIA, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel LOPEZ-TRABADA-ATAZ, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Strasbourg - HÃ´pital Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Emmanuel KURTZ, Pr</last_name>
      <phone>+33 3 88 12 78 82</phone>
      <email>emmanuel.kurtz@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Laure DE COCK, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laure PIERARD, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Blackstein ME, Blay JY, Corless C, Driman DK, Riddell R, SouliÃ¨res D, Swallow CJ, Verma S; Canadian Advisory Committee on GIST. Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment. Can J Gastroenterol. 2006 Mar;20(3):157-63.</citation>
    <PMID>16550259</PMID>
  </reference>
  <reference>
    <citation>Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD, Roberts PJ, Heinz D, Wehre E, Nikolova Z, Joensuu H. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008 Feb 1;26(4):620-5. doi: 10.1200/JCO.2007.13.4403.</citation>
    <PMID>18235121</PMID>
  </reference>
  <reference>
    <citation>Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008 Feb 1;26(4):626-32. doi: 10.1200/JCO.2007.13.4452.</citation>
    <PMID>18235122</PMID>
  </reference>
  <reference>
    <citation>Blay JY, von Mehren M, Blackstein ME. Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors. Cancer. 2010 Nov 15;116(22):5126-37. doi: 10.1002/cncr.25267. Review.</citation>
    <PMID>20661913</PMID>
  </reference>
  <reference>
    <citation>Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C, Adenis A, Viens P, Rios M, Bompas E, Cupissol D, Guillemet C, Kerbrat P, Fayette J, Chabaud S, Berthaud P, Perol D. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol. 2007 Mar 20;25(9):1107-13.</citation>
    <PMID>17369574</PMID>
  </reference>
  <reference>
    <citation>Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY; ESMO Guidelines Working Group. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008 May;19 Suppl 2:ii35-8. doi: 10.1093/annonc/mdn080.</citation>
    <PMID>18456761</PMID>
  </reference>
  <reference>
    <citation>ClinicalTrials.gov. Imatinib mesilate or observation only in treating patients who have undergone surgery for localized gastrointestinal stromal tumor. NCT identifier: NCT00103168. 13-12-2009. Ref Type: Online Source</citation>
  </reference>
  <reference>
    <citation>ClinicalTrials.gov. Five year adjuvant imatinib mesilate (GleevecÂ®) in gastrointestinal stromal tumor (GIST). NCT Identifier: NCT00867113. 24-8-2011. Ref Type: Online Source</citation>
  </reference>
  <reference>
    <citation>Corless CL, Heinrich MC. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol. 2008;3:557-86. Review.</citation>
    <PMID>18039140</PMID>
  </reference>
  <reference>
    <citation>Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011 Nov 17;11(12):865-78. doi: 10.1038/nrc3143. Review.</citation>
    <PMID>22089421</PMID>
  </reference>
  <reference>
    <citation>Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Mar 28;373(9669):1097-104. doi: 10.1016/S0140-6736(09)60500-6. Epub 2009 Mar 18. Erratum in: Lancet. 2009 Aug 8;374(9688):450.</citation>
    <PMID>19303137</PMID>
  </reference>
  <reference>
    <citation>DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000 Jan;231(1):51-8.</citation>
    <PMID>10636102</PMID>
  </reference>
  <reference>
    <citation>Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol. 2002 May;33(5):466-77.</citation>
    <PMID>12094371</PMID>
  </reference>
  <reference>
    <citation>Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002 Aug 15;347(7):472-80.</citation>
    <PMID>12181401</PMID>
  </reference>
  <reference>
    <citation>Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, Pisters PW, Raut CP, Riedel RF, Schuetze S, Sundar HM, Trent JC, Wayne JD. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010 Apr;8 Suppl 2:S1-41; quiz S42-4.</citation>
    <PMID>20457867</PMID>
  </reference>
  <reference>
    <citation>Patrikidou A, Chabaud S, Ray-Coquard I, Bui BN, Adenis A, Rios M, Bertucci F, Duffaud F, Chevreau C, Cupissol D, Domont J, PÃ©rol D, Blay JY, Le Cesne A; French Sarcoma Group. Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. Ann Oncol. 2013 Apr;24(4):1087-93. doi: 10.1093/annonc/mds587. Epub 2012 Nov 21.</citation>
    <PMID>23175622</PMID>
  </reference>
  <reference>
    <citation>Gold JS, GÃ¶nen M, GutiÃ©rrez A, Broto JM, GarcÃ­a-del-Muro X, Smyrk TC, Maki RG, Singer S, Brennan MF, Antonescu CR, Donohue JH, DeMatteo RP. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 2009 Nov;10(11):1045-52. doi: 10.1016/S1470-2045(09)70242-6. Epub 2009 Sep 28.</citation>
    <PMID>19793678</PMID>
  </reference>
  <reference>
    <citation>H.Joensuu, M.Eriksson, J.Hatrmann, K.Sundby Hall, J.Schutte, A. Reichardt, M.Schlemmer, E. Wardelmann, G.Ramadori, S. E. Al-Batran B. E. Nilsson O. Monge R. Kallio, and M.Sarlomo-Rikala, P. Bono M. Leinonen P. Hohenberger T. Alvegard P. Reichardt. Three years of imatinib improves survival for high-risk gastrointestinal stromal tumours. ASCO 2011 . 2011. Ref Type: Abstract</citation>
  </reference>
  <reference>
    <citation>Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003 Dec 1;21(23):4342-9.</citation>
    <PMID>14645423</PMID>
  </reference>
  <reference>
    <citation>Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998 Jan 23;279(5350):577-80.</citation>
    <PMID>9438854</PMID>
  </reference>
  <reference>
    <citation>Jiang WZ, Guan GX, Lu HS, Yang YH, Kang DY, Huang HG. Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months. J Surg Oncol. 2011 Dec;104(7):760-4. doi: 10.1002/jso.22010. Epub 2011 Jun 28.</citation>
    <PMID>21713778</PMID>
  </reference>
  <reference>
    <citation>Joensuu,H. and Ericksson,M.H.J. (2011). Twelve versus 36 monts of adjuvant imatinib as treatment of operable GIST with high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO). J. Clin. Oncol.</citation>
  </reference>
  <reference>
    <citation>Joensuu H, Vehtari A, RiihimÃ¤ki J, Nishida T, Steigen SE, Brabec P, Plank L, Nilsson B, Cirilli C, Braconi C, Bordoni A, Magnusson MK, Linke Z, Sufliarsky J, Federico M, Jonasson JG, Dei Tos AP, Rutkowski P. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012 Mar;13(3):265-74. doi: 10.1016/S1470-2045(11)70299-6. Epub 2011 Dec 6. Review.</citation>
    <PMID>22153892</PMID>
  </reference>
  <reference>
    <citation>Le Cesne,A., Ray-Coquard,I.L., Bui Nguyen,B., Adenis,A., Rios,M., Bertucci,F., Duffaud,F., Cupissol,D., Chevreau,C., Bompas,E., Cioffi,A., Chabaud,S., Perol,D., and Blay,J. (2011). Time to secondary resistance (TSR) after interruption of imatinib (IM) in advanced GIST: Updated results of the prospective French Sarcoma Group randomized phase III trial on long-term survival. ASCO Meeting Abstracts 29, 10015.</citation>
  </reference>
  <reference>
    <citation>Le Cesne A, Ray-Coquard I, Bui BN, Adenis A, Rios M, Bertucci F, Duffaud F, Chevreau C, Cupissol D, Cioffi A, Emile JF, Chabaud S, PÃ©rol D, Blay JY; French Sarcoma Group. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol. 2010 Oct;11(10):942-9. doi: 10.1016/S1470-2045(10)70222-9. Epub 2010 Sep 21.</citation>
    <PMID>20864406</PMID>
  </reference>
  <reference>
    <citation>Pisters PW, Colombo C. Adjuvant imatinib therapy for gastrointestinal stromal tumors. J Surg Oncol. 2011 Dec;104(8):896-900. doi: 10.1002/jso.22002. Review.</citation>
    <PMID>22069174</PMID>
  </reference>
  <reference>
    <citation>Ray-Coquard,I.L., Bin Bui,N., Adenis,A., Rios,M., Bertucci,F., Chabaud,S., Perol,D., Blay,J., Le Cesne,A., and Groupe Sarcome Francais &amp; Groupe d'Etude des Tumeurs Osseuses (GSF-GETO) (2010). Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: Results of the prospective BFR14 randomized phase III study comparing interruption versus continuation of IM at 5 years of treatment: A French Sarcoma Group Study. ASCO Meeting Abstracts 28, 10032.</citation>
  </reference>
  <reference>
    <citation>Tryggvason G, GÃ­slason HG, MagnÃºsson MK, JÃ³nasson JG. Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer. 2005 Nov 1;117(2):289-93.</citation>
    <PMID>15900576</PMID>
  </reference>
  <reference>
    <citation>Tzen CY, Wang JH, Huang YJ, Wang MN, Lin PC, Lai GL, Wu CY, Tzen CY. Incidence of gastrointestinal stromal tumor: a retrospective study based on immunohistochemical and mutational analyses. Dig Dis Sci. 2007 Mar;52(3):792-7.</citation>
    <PMID>17253141</PMID>
  </reference>
  <reference>
    <citation>Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, Bertulli R, Judson I. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34.</citation>
    <PMID>15451219</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2014</study_first_submitted>
  <study_first_submitted_qc>October 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2014</study_first_posted>
  <last_update_submitted>August 4, 2017</last_update_submitted>
  <last_update_submitted_qc>August 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastrointestinal Stromal Tumors</keyword>
  <keyword>Non-metastatic</keyword>
  <keyword>KIT +</keyword>
  <keyword>Imatinib</keyword>
  <keyword>Adjuvant treatment</keyword>
  <keyword>High risk of recurrence</keyword>
  <keyword>Tyrosine kinase inhibitor</keyword>
  <keyword>Disease Free Survival</keyword>
  <keyword>Overall survival</keyword>
  <keyword>Time To Secondary Resistance</keyword>
  <keyword>Safety profile</keyword>
  <keyword>Quality of Life during treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

